CBTF Programs and Research

The FDA granted LSTA1 rare pediatric disease designation for the treatment of osteosarcoma.

Jacki Garcia, RN, BSN, CNRN; and Kristin Hendrickson, BA, RN, discuss phase 0 trials and how they can help expedite the research process for brain cancer therapies.

A treatment for NTRK-positive locally advanced or metastatic solid tumors, repotrectinib, is currently under priority review by the FDA and may address a high unmet medical need.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Oncology nurses can bring creative art to their pediatric patients with cancer, thereby potentially reducing their anxiety levels, research showed.

Eflornithine (Iwilfin) received FDA approval to reduce the risk for relapse in pediatric and adult patients with high-risk neuroblastoma, making it the first therapy to reduce risk for relapse in children with the disease.